PL2624833T3 - Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów - Google Patents
Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworówInfo
- Publication number
- PL2624833T3 PL2624833T3 PL11773326T PL11773326T PL2624833T3 PL 2624833 T3 PL2624833 T3 PL 2624833T3 PL 11773326 T PL11773326 T PL 11773326T PL 11773326 T PL11773326 T PL 11773326T PL 2624833 T3 PL2624833 T3 PL 2624833T3
- Authority
- PL
- Poland
- Prior art keywords
- methylaminophenoxy
- pyrdin
- treating cancer
- benzamide derivatives
- benzamide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38939310P | 2010-10-04 | 2010-10-04 | |
| EP20110773326 EP2624833B1 (en) | 2010-10-04 | 2011-10-03 | 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer |
| PCT/JP2011/073165 WO2012046825A1 (en) | 2010-10-04 | 2011-10-03 | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2624833T3 true PL2624833T3 (pl) | 2015-05-29 |
Family
ID=44872549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11773326T PL2624833T3 (pl) | 2010-10-04 | 2011-10-03 | Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US8946437B2 (pl) |
| EP (1) | EP2624833B1 (pl) |
| JP (1) | JP5715690B2 (pl) |
| KR (1) | KR101797797B1 (pl) |
| CN (1) | CN103189061B (pl) |
| AR (1) | AR083287A1 (pl) |
| AU (1) | AU2011313236B2 (pl) |
| BR (1) | BR112013007841B1 (pl) |
| CA (1) | CA2813153C (pl) |
| CO (1) | CO6660459A2 (pl) |
| DK (1) | DK2624833T3 (pl) |
| EA (1) | EA021627B1 (pl) |
| ES (1) | ES2526574T3 (pl) |
| HR (1) | HRP20141237T1 (pl) |
| IL (1) | IL225520A (pl) |
| MX (1) | MX2013003589A (pl) |
| MY (1) | MY157563A (pl) |
| NZ (1) | NZ609151A (pl) |
| PH (1) | PH12013500605B1 (pl) |
| PL (1) | PL2624833T3 (pl) |
| PT (1) | PT2624833E (pl) |
| RS (1) | RS53749B1 (pl) |
| SG (1) | SG189146A1 (pl) |
| SI (1) | SI2624833T1 (pl) |
| SM (1) | SMT201500056B (pl) |
| TW (1) | TWI526431B (pl) |
| UA (1) | UA110037C2 (pl) |
| WO (1) | WO2012046825A1 (pl) |
| ZA (1) | ZA201302332B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY157563A (en) * | 2010-10-04 | 2016-06-30 | Otsuka Pharma Co Ltd | 4- (methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer |
| JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
| WO2020196665A1 (en) * | 2019-03-25 | 2020-10-01 | Otsuka Pharmaceutical Co., Ltd. | Antitumor composition |
| CN118005541B (zh) * | 2023-12-13 | 2025-05-30 | 张家港格瑞特化学有限公司 | 一种双牛磺酸盐及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
| MX2007001215A (es) | 2004-08-06 | 2007-04-17 | Otsuka Pharma Co Ltd | Compuestos aromaticos. |
| MY146514A (en) * | 2005-12-05 | 2012-08-15 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| MY157563A (en) * | 2010-10-04 | 2016-06-30 | Otsuka Pharma Co Ltd | 4- (methylaminophenoxy) pyrdin-3-yl-benzamide derivatives for treating cancer |
| WO2020196665A1 (en) * | 2019-03-25 | 2020-10-01 | Otsuka Pharmaceutical Co., Ltd. | Antitumor composition |
-
2011
- 2011-10-03 MY MYPI2013001147A patent/MY157563A/en unknown
- 2011-10-03 RS RS20150024A patent/RS53749B1/sr unknown
- 2011-10-03 MX MX2013003589A patent/MX2013003589A/es active IP Right Grant
- 2011-10-03 SI SI201130409T patent/SI2624833T1/sl unknown
- 2011-10-03 SG SG2013023148A patent/SG189146A1/en unknown
- 2011-10-03 TW TW100135750A patent/TWI526431B/zh active
- 2011-10-03 CA CA2813153A patent/CA2813153C/en active Active
- 2011-10-03 ES ES11773326.1T patent/ES2526574T3/es active Active
- 2011-10-03 EA EA201390323A patent/EA021627B1/ru unknown
- 2011-10-03 CN CN201180047707.2A patent/CN103189061B/zh active Active
- 2011-10-03 AR ARP110103657 patent/AR083287A1/es unknown
- 2011-10-03 EP EP20110773326 patent/EP2624833B1/en active Active
- 2011-10-03 PT PT11773326T patent/PT2624833E/pt unknown
- 2011-10-03 US US13/877,276 patent/US8946437B2/en active Active
- 2011-10-03 PH PH1/2013/500605A patent/PH12013500605B1/en unknown
- 2011-10-03 KR KR1020137008052A patent/KR101797797B1/ko active Active
- 2011-10-03 NZ NZ60915111A patent/NZ609151A/en unknown
- 2011-10-03 PL PL11773326T patent/PL2624833T3/pl unknown
- 2011-10-03 WO PCT/JP2011/073165 patent/WO2012046825A1/en not_active Ceased
- 2011-10-03 JP JP2013515439A patent/JP5715690B2/ja active Active
- 2011-10-03 IL IL225520A patent/IL225520A/en active IP Right Grant
- 2011-10-03 DK DK11773326T patent/DK2624833T3/en active
- 2011-10-03 UA UAA201303865A patent/UA110037C2/uk unknown
- 2011-10-03 BR BR112013007841-3A patent/BR112013007841B1/pt active IP Right Grant
- 2011-10-03 AU AU2011313236A patent/AU2011313236B2/en active Active
- 2011-10-03 HR HRP20141237AT patent/HRP20141237T1/hr unknown
-
2013
- 2013-03-28 ZA ZA2013/02332A patent/ZA201302332B/en unknown
- 2013-04-16 CO CO13097703A patent/CO6660459A2/es unknown
-
2014
- 2014-12-17 US US14/574,102 patent/US20150105432A1/en not_active Abandoned
-
2015
- 2015-03-09 SM SM201500056T patent/SMT201500056B/xx unknown
-
2016
- 2016-11-28 US US15/362,561 patent/US20170298023A1/en not_active Abandoned
-
2018
- 2018-05-02 US US15/969,690 patent/US20180265471A1/en not_active Abandoned
-
2019
- 2019-06-13 US US16/440,924 patent/US20200031773A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/039,731 patent/US20210017134A1/en not_active Abandoned
-
2022
- 2022-12-30 US US18/148,672 patent/US20230139808A1/en not_active Abandoned
-
2024
- 2024-08-26 US US18/814,803 patent/US20240417376A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL223201A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| PL2440545T3 (pl) | Związki użyteczne do leczenia nowotworu | |
| PL3967315T3 (pl) | Akkermansia muciniphila do leczenia nowotworu złośliwego | |
| EP2542585B8 (en) | Methods for treating colorectal cancer | |
| SI2902030T1 (sl) | Tienotriazolodiazepinske spojine za zdravljenje neoplazije | |
| HUE048639T2 (hu) | Eljárás DLBCL kezelésére | |
| EP2542584B8 (en) | Methods for treating pancreatic cancer | |
| SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
| IL228644A0 (en) | Cancer treatment methods | |
| ZA201203449B (en) | Sulfoxide derivatives for treating tumors | |
| IL225623A0 (en) | Psoriasis treatment methods | |
| IL222958A0 (en) | Cancer treatment | |
| HRP20160851T1 (hr) | Prediktori za liječenje karcinoma | |
| ZA201503005B (en) | Ingenol-derived compounds useful for treating cancer | |
| IL225520A0 (en) | History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment | |
| PL2663318T3 (pl) | Kompozycja farmaceutyczna do leczenia raka | |
| WO2011137376A9 (en) | Compounds for anti-fungal treatment | |
| GB201019034D0 (en) | Treatment for tumors | |
| GB0914322D0 (en) | Compounds for treating cancer | |
| AU2012901918A0 (en) | Methods for treating cancer | |
| GB201010588D0 (en) | Cancer treatment | |
| ZA201405068B (en) | Piperazinyl derivatives for the treatment of cancer |